Etan Orgel, MD

Professor of Clinical Pediatrics

Image of Etan Orgel, MD
Is this your profile? Click to edit

Overview

Dr. Orgel is an attending physician in the Cancer and Blood Disease Institute at the Children’s Hospital Los Angeles (Los Angeles, CA). Dr. Orgel’s clinical specialty is in treating higher risk and rare malignant hematology. He is an international expert in treating Mixed-Phenotype Acute Leukemia (MPAL), a particularly rare form of leukemia. He possesses an academic appointment as a Professor of Clinical Pediatrics in the Keck School of Medicine of the University of Southern California (USC) and earned a Masters of Science in Clinical and Biomedical Investigations from the Department of Preventive Medicine at USC.

Dr. Orgel’s primary research interest lies in the field of cancer control (reducing acute and long-term treatment-related toxicities). Dr. Orgel leads a translational research program focused on reducing toxicities from common chemotherapies with the goal of improving both treatment delivery and quality of life for children with cancer. Dr. Orgel’s investigator-initiated research currently includes two primary areas of emphasis (1) new agents and novel strategies to reduce chemotherapy-induced hearing loss, and (2) targeting overweight and obesity in pediatric ALL to reduce chemoresistance, toxicity, and relapse.

Publications

  • When one size does not fit all: evaluating urine culture stewardship strategies for high-risk pediatric patients. J Clin Microbiol. 2026 Nov 11.. View in PubMed
  • Complications in Pediatric Cancer Patients With Staphylococcus aureus Bloodstream Infection. Pediatrics. 2026 Nov 04.. View in PubMed
  • Obesity’s Impact on Prognosis in Ph-Like Acute Lymphoblastic Leukemia. Pediatr Blood Cancer. 2026 Oct 07.. View in PubMed
  • Diagnostic BMI and Induction Therapy Weight Change Associated With Hepatotoxicity in Pediatric Patients With Acute Lymphoblastic Leukemia. Cancer Med. 2026 Sep; 15(9):e72218.. View in PubMed
  • Neurofilament Light Chain: A Potential Biomarker for Chemotherapy-Induced Peripheral Neuropathy in Pediatric and Adolescent Young Adults with Leukemia or Lymphoma. Cancers (Basel). 2026 Aug 25; 18(17).. View in PubMed
  • Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children’s Oncology Group. Blood Adv. 2026 07 28; 10(14):4923-4930.. View in PubMed
  • On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi-Center Phase-III Randomized Clinical Trials. Pediatr Blood Cancer. 2026 Sep; 73(9):e70593.. View in PubMed
  • Neurofilament Light Chain: A Potential Biomarker for Chemotherapy-Induced Peripheral Neuropathy in Adolescent Young Adults. J Adolesc Young Adult Oncol. 2026 Jul 01; 21565333261464963.. View in PubMed
  • Impact of Cisplatin-Induced Hearing Loss on Quality of Life in Childhood Cancer Survivors. JCO Oncol Pract. 2026 Jun 22.. View in PubMed
  • Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies. Am Soc Clin Oncol Educ Book. 2026 Jun; 46(3):e517242.. View in PubMed